National drug regulators in Europe have ordered a recall of all batches of Amgen’s Tavneos (avacopan) after the European Commission formally canceled the drug’s marketing authorization earlier this month. The recall escalates a regulatory reversal for the vasculitis treatment and raises immediate questions for patients, distributors, and physicians managing ongoing care. Amgen is now facing the operational fallout typically associated with withdrawn approvals, including batch disposition and potential continuity-of-therapy planning. Tavneos previously competed in a space where treatment protocols are tightly linked to reimbursement, inpatient referral pathways, and prescribing norms. For the broader biotech sector, the action highlights the speed at which EU authorizations can be reversed and the importance of EU-specific post-authorization obligations, pharmacovigilance, and manufacturing oversight. It also signals how cross-agency decisions can quickly translate into real-world drug availability constraints. Investors will likely focus on the magnitude of the authorization change and the remediation steps Amgen would need to address to restore an EU pathway for the therapy.